GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Transgene Biotek Ltd (BOM:526139) » Definitions » Shiller PE Ratio

Transgene Biotek (BOM:526139) Shiller PE Ratio : (As of Apr. 13, 2025)


View and export this data going back to 2001. Start your Free Trial

What is Transgene Biotek Shiller PE Ratio?

Shiller PE for Stocks: The True Measure of Stock Valuation


Transgene Biotek Shiller PE Ratio Historical Data

The historical data trend for Transgene Biotek's Shiller PE Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Transgene Biotek Shiller PE Ratio Chart

Transgene Biotek Annual Data
Trend Mar15 Mar16 Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23 Mar24
Shiller PE Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

Transgene Biotek Quarterly Data
Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24
Shiller PE Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of Transgene Biotek's Shiller PE Ratio

For the Biotechnology subindustry, Transgene Biotek's Shiller PE Ratio, along with its competitors' market caps and Shiller PE Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Transgene Biotek's Shiller PE Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Transgene Biotek's Shiller PE Ratio distribution charts can be found below:

* The bar in red indicates where Transgene Biotek's Shiller PE Ratio falls into.


;
;

Transgene Biotek Shiller PE Ratio Calculation

For Shiller PE Ratio, the earnings of the past 10 years are inflation-adjusted and averaged. The result is used for P/E calculation. Since it looks at the average over the last 10 years, the Shiller PE Ratio is also called PE10.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The same calculation is applied here to individual companies.

Transgene Biotek's E10 for the quarter that ended in Dec. 2024 is calculated as:

For example, Transgene Biotek's adjusted earnings per share data for the three months ended in Dec. 2024 was:

Adj_EPS=Earnings per Share (Diluted)/CPI of Dec. 2024 (Change)*Current CPI (Dec. 2024)
=-0.01/158.3229*158.3229
=-0.010

Current CPI (Dec. 2024) = 158.3229.

Transgene Biotek Quarterly Data

Earnings per Share (Diluted) CPI Adj_EPS
200903 0.000 56.615 0.000
201003 0.000 65.030 0.000
201103 0.000 70.768 0.000
201203 0.000 76.889 0.000
201206 1.970 79.567 3.920
201209 -0.210 82.244 -0.404
201212 0.860 83.774 1.625
201303 -1.750 85.687 -3.233
201403 0.000 91.425 0.000
201503 0.000 97.163 0.000
201603 0.000 102.518 0.000
201703 0.000 105.196 0.000
201803 0.000 109.786 0.000
201806 -0.330 111.317 -0.469
201809 -0.350 115.142 -0.481
201812 -0.120 115.142 -0.165
201903 -0.357 118.202 -0.478
201906 -0.370 120.880 -0.485
201909 -0.360 123.175 -0.463
201912 -0.350 126.235 -0.439
202003 -0.369 124.705 -0.468
202006 -0.350 127.000 -0.436
202009 -0.350 130.118 -0.426
202012 -0.330 130.889 -0.399
202103 -0.347 131.771 -0.417
202106 -0.340 134.084 -0.401
202109 -0.340 135.847 -0.396
202112 -0.350 138.161 -0.401
202203 -0.332 138.822 -0.379
202206 -0.180 142.347 -0.200
202209 -0.230 144.661 -0.252
202212 -0.180 145.763 -0.196
202303 -0.190 146.865 -0.205
202306 -0.020 150.280 -0.021
202309 -0.020 151.492 -0.021
202312 -0.020 152.924 -0.021
202403 -0.040 153.035 -0.041
202406 0.030 155.789 0.030
202409 -0.010 157.882 -0.010
202412 -0.010 158.323 -0.010

Add all the adjusted EPS together and divide 10 will get our E10.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


Transgene Biotek  (BOM:526139) Shiller PE Ratio Explanation

Compared with the regular PE Ratio, which works poorly for cyclical businesses, the Shiller PE Ratio smoothed out the fluctuations of profit margins during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Shiller PE Ratio should give similar results to regular PE Ratio.

Compared with the PS Ratio, the Shiller PE Ratio makes the comparison between different industries more meaningful.


Be Aware

Shiller PE Ratio assumes that over the long term, businesses and profitability revert to their means. If a company's business model does not work in the future compared with the past, Shiller PE Ratio and PS Ratio will give false valuations.


Transgene Biotek Shiller PE Ratio Related Terms

Thank you for viewing the detailed overview of Transgene Biotek's Shiller PE Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Transgene Biotek Business Description

Traded in Other Exchanges
N/A
Address
Anrich Industrial Area, Plot No. 69 and 70, IDA Bollaram, Sangareddy District, Medak, TG, IND, 502325
Transgene Biotek Ltd is an India-based research and development company. It is engaged in the research and development of molecules and technologies for the production of active pharmaceutical ingredients and other pharmaceutical products. The company is operating only in one segment of Bulk Drugs. Its product portfolio includes TrabiDHA, Tracolimus, and Orlistat. It generates revenue from the sale of goods and services.

Transgene Biotek Headlines

No Headlines